Featured
Telstra this week posted a solid 31% full-year profit boost, but investors may be able to dial up better value elsewhere in the sector.
Lion Selection Group’s Hedley Widdup says the humble developers have been the standout gold stock class of 2025 so far.
The ASX healthcare sector, up over the past five days, has had a “reasonable start” to reporting season, notes Morgans’ Scott Power.
Neurizon Therapeutics’ drug candidate NUZ-001 FDA review to lift the clinical hold has been delayed until October 3rd.
Tour guide names best value country and what you’ll always find in her carry-on. This traveller likes to leave the worrying to someone else.
